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Abstract: Thoracic malignancies comprise some of the most common and deadly cancers.
Immunotherapies have been proven to improve survival outcomes for patients with advanced nonsmall cell lung cancer (NSCLC) and show great potential for patients with other thoracic malignancies.
Radiation therapy (RT), an established and effective treatment for thoracic cancers, has acted synergistically
with immunotherapies in preclinical studies. Ongoing clinical trials are exploring the clinical benefits of
combining RT with immunotherapies and the optimal manner in which to deliver these complementary
treatments.
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Introduction
Thoracic malignancies, consisting predominantly of nonsmall cell lung cancer (NSCLC) and small cell lung cancer
(SCLC), have a predilection for distant metastasis and are
associated with a poor prognosis (1). Similar outcomes are
seen in other cancers of the thorax including malignant
pleural mesothelioma (MPM) (2), advanced esophageal
cancers (3), advanced stage thymoma, and thymic
carcinoma (4). Clearly, novel therapies are needed for these
patients to improve tumor control and survival.
In recent years the benefit of immunotherapy, which
harnesses the body’s ability to eliminate cancer cells, has
emerged for some patients with thoracic malignancies.
In fact, the influence of immunotherapy has been so
profound that Science magazine named immunotherapy
as the “Breakthrough of the Year” in 2013 (5), and
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it is now considered to be the fourth pillar of cancer
care (6). The spotlight has focused especially on immune
checkpoint inhibitors (ICIs) (7,8), although other types
of immunotherapies including tumor vaccines and
chimeric antigen receptor (CAR) T-cell therapy are also
promising (9,10).
While immunotherapy alone has shown impressive
results in patients with NSCLC beyond what is achievable
with conventional therapies, the majority of patients
will not achieve such responses. In fact, immunotherapy
monotherapy is expected to result in significant benefits
for only a subset of patients, especially those with high
tumor mutational burden (11). Fortunately, emerging
data demonstrate anti-tumor effects may increase with
the use of immunotherapy in combinatorial regimens,
including dual immune checkpoint blockade (12,13) as
well as immunotherapy plus local tumor treatment such as
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radiation therapy (RT) (14).
While radiation has direct cytotoxic effects on cancer
cells, it is well established that RT is capable of generating
a robust anti-tumor immune response through effects on
the tumor and the tumor microenvironment via a variety of
mechanisms including enhanced tumor antigen presentation
and upregulated major histocompatibility complex (MHC)
class I expression (15). An abundance of preclinical studies
demonstrates that radiation combined with checkpoint
blockade results in a synergistic effect (16). While the
optimal combination in cancer patients remains unclear,
there are emerging clinical outcomes data suggesting that
RT may, in fact, have systemic effects that go far beyond the
locally irradiated target (17,18).
Herein, we review the preclinical data and clinical
outcomes that support the use of radiation and
immunotherapy for patients with thoracic malignancies. We
also discuss ongoing clinical trials that aim to further expand
our understanding of how this treatment combination may
further improve the therapeutic index for these patients.
Preclinical rationale for combining radiation
with ICIs
The tissue microenvironment (TME) of the lung
The TME is a complex interplay of neutrophils, T-regulatory
cells (Tregs), and myeloid-derived suppressor cells (MDSCs).
There are pattern recognition receptors expressed by
epithelial cells that can recognize and respond to pathogens
through various pathways, as well as kill pathogens via
these mechanisms (19,20). The ratio of specific subtypes of
immune cells has been shown to be associated with survival
in NSCLC, with inactivated mast cells, inactivated CD4+
memory T-cells, and naïve and memory B cells and plasma
cells having favorable prognosis in adenocarcinomas; whereas
higher abundance of myeloid populations and activated
CD4+ memory T-cells are associated with poor prognosis
in squamous cell carcinomas (21). Many studies evaluating
various interactions of these immune cells have been
performed, and overall the tumor assisted macrophages
(TAMs), neutrophils, MDSCs, and Tregs all play a role in
the TME, with increased T-cell infiltration into tumor,
mature dendritic cells, and B cells correlating with favorable
prognosis (22).
RT and immune cell response
RT has immunomodulation features within the lung
© Journal of Thoracic Disease. All rights reserved.
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parenchyma that can elicit contradictory host responses. RT
can beneficially enhance recognition of tumor antigens by
augmenting the immune system’s response to the tumor via
increased MHC class 1 expression (23). RT has also been
shown to increase levels of transforming growth factorbeta (TGF-β), which can increase Treg representation
after RT (24), resulting in a decrease in the response to
therapy. RT also recruits MDSCs and macrophages, which
in the presence of TGF-β can become M2 polarized and
promote tumor growth, invasion and metastasis (25).
Other preclinical work focusing on the immune response
of varying RT fractionation schemes shows a difference in
immune cell recruitment with fractionation, noting more
CD8+ recruitment in higher dose-per-fraction (30 Gy in 1
fraction) schemes compared to more MDSC recruitment
with more fractionated approaches (3 Gy ×10 fractions)
(26-28). As a result of the varying ways that RT can
influence the immune system, clinical responses have been
mixed.
Rationale for the combination of ICIs and RT
The two most actively studied immune-checkpoint
receptors are both inhibitory receptors: cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4) and
programmed cell death protein 1 (PD-1). In general,
inhibitory ligands and receptors that regulate T-cell effector
functions are overexpressed on tumor cells, while costimulatory receptors that regulate T-cell activation are not
overexpressed (29). One of the most common mechanisms
of immune checkpoint blockade is antibodies to the PD-1
receptor. The role of PD-1 is to limit the activity of T-cells
in peripheral tissues at the time of an inflammatory response
to infection in order to minimize autoimmunity (30-36).
However, in the TME, this process can result in effective
immune resistance (37-39).
Inhibition of this checkpoint affects membrane proteins
that are located on a range of cells including T-cells, B
cells, natural killer (NK) cells, activated monocytes, and
dendritic cells (36). Tumor cells frequently express the
ligand programmed death-ligand 1 (PD-L1) on their
surface, which when bound by PD-1, downregulate antigen
receptor signaling resulting in decreased T-cell proliferation
and cytokine production, limiting the activity of effector
cells (40). Additionally, PD-1 has been found to be
overstimulated and tumor-specific on T-cells (41). Increased
expression of PD-L1 has been shown to result in lower
numbers of tumor infiltrating lymphocytes (TILs) (42), and
jtd.amegroups.com
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higher expression of PD-L1 on tumor cells has been shown to
correlate with better response to PD-1 antibody therapy (43).
The second most common checkpoint inhibitor is
targeted to a receptor on T-cells known as CTLA-4,
which has a high affinity for Tregs. Through its binding
interaction with CD80 and CD86 (which limits binding
of these to CD28) on antigen presenting cells (APCs),
it both promotes Treg immunosuppressive function and
sends inhibitory signaling to T-cells (29). With the greater
affinity of binding of CTLA-4 to CD80 and CD86 over
CD28, there is a negative feedback loop that leads to T-cell
activation and increased CTLA-4 expression in order to
prevent autoimmune reactions (44). Finally, murine models
have demonstrated that the primary mode of action of antiCTLA-4 drugs is primarily by depleting Tregs via antibodydependent cell-mediated cytotoxicity (45).
Based on the promising preclinical data combining
RT and immune checkpoint blockers for non-thoracic
malignancies, a number of investigators have explored
the efficacy of the combination in preclinical NSCLC
models. An initial study of KRAS-mutant NSCLC showed
improved survival and tumor shrinkage when combining
RT and an anti-PD-1 antibody compared to either modality
alone (46). Studies have indicated that this synergy may be
the result of RT overcoming PD-1inhibitor resistance via
induction of type I interferon (IFN) production leading to
enhanced MHC class 1 expression (47). This combination
may be promising for translation into the clinic for patients
who initially become resistant to anti-PD-1 therapy as a
way to increase responsiveness to therapy.
CTLA-4 blockade has also been studied in preclinical
lung cancer mouse models in combination with RT (48).
Yoshimoto et al. found that RT alone doubled median
survival, and the addition of anti-CTLA-4 antibody
increased the anti-tumor activity of RT by prolonging the
tumor growth delay from 13.1 to 19.5 days. Another study
combining RT with anti-CD25 therapy led to decreased
Tregs in the spleen and the tumor when compared to
monotherapy in an LL/C mouse model (49).
Preclinical studies have also demonstrated potential
synergetic effects when combining RT with ICIs. PD-1
blockade enhances T-cells, driving immune response and
increasing effector cell activity, while CTLA-4 blockade
depletes inhibitory Tregs (50). Additionally, RT alone can
influence the immune system in a multitude of ways, some
of which enhance tumor response while others render
further RT less effective. However, the combination of RT
and immune checkpoint blockade has the ability to enhance
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effects of either one of these therapies alone (and even
overcome ineffectiveness of monotherapy), providing an
exciting interdisciplinary approach to the management of
NSCLC (51).
Preclinical rationale for combining radiation with
immunotherapy beyond checkpoint inhibitors
Modulation of ICIs targeting receptors such as CTLA-4
and PD-L1 is backed by compelling data as demonstrated
in recent Checkmate trials (52,53). While promising,
checkpoint inhibition as a treatment strategy benefits
only a limited population of patients. Accordingly, other
immunomodulatory techniques have been investigated
including the use of T-cells that have been genetically
modified to target cancer specific CARs.
Basic principles of CAR T-cell therapy
The ability to evade growth suppression and circumvent
immunosurveillance is a distinct feature of cancer
cells (54). This hallmark characteristic is mediated, in
part, by the downregulation of the class 1 MHC proteins.
The crux of CAR T-cell therapy is based on genetically
engineering a T-cell with a CAR that can recognize
cancer cells independent of MHC proteins. While the
theory of T-cell mediated therapy is not new, advances in
molecular synthesis have elevated this strategy as an exciting
therapeutic option (55-58).
Constructing these modified T-cells requires attention
to two major components: an intracellular transmembrane
component and an extracellular, tumor-recognition
component. The development of these genetically
engineered T-cells has been characterized by increasingly
complex co-stimulatory activation domains within the
intracellular component to achieve a sustainable T-cell
response. Specifically, the first generation of CAR T-cells
contained a CD-3ζ containing domain, while additional
domains including CD28, OX40 or 4-1BB now characterize
the latest generation of CAR T-cells. Equally, the
extracellular component must be designed for a specific
target on cancer cells to maximize efficacy while minimizing
the potential for “on target, off tumor” effects where nonpathologic tissues are targeted (59).
Challenges to effective CAR T-cell therapy
The use of CAR T-cells in solid tumors presents the unique
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challenge of effectively trafficking the genetically engineered
T-cells to the target and propagating this response in a
hostile tumor microenvironment. The mechanisms that
govern the trafficking of native T-cells (adhesion, tethering,
chemotaxis, and extravasation) are hindered at each phase
by factors specific to the tumor microenvironment. For
example, tumor-promoted angiogenesis yields vessels with
endothelial cells lacking the necessary molecules for T-cells
adherence (60). Furthermore, the physical barrier created
by the rich stroma of solid tumors hampers the penetration
and aggregation of engineered T-cells that lack the enzyme
heparanase (61). Moreover, once T-cells have penetrated,
molecular signaling in the tumor microenvironment is
immunosuppressive and down regulates the recruitment
and aggregation of additional T-cells (62-65).

complimentary immunomodulator with the potential
to help overcome many of the difficulties surrounding
effective CAR T-cell therapy and function beyond its
cytotoxic effects. While clinical outcomes of this approach
are more limited than combining radiotherapy with ICIs, to
further optimize the radiotherapy-CAR T cell combination
approach, topics such as the timing of radiation relative to
CAR T-cell therapy and the ideal dose and fractionation
of radiotherapy will need to be addressed. CART T-cell
therapy is currently under investigation for metastatic
NSCLC in a phase II clinical trial at the National Institutes
of Health (NCT02133196). The combination CAR T-cell
therapy and radiation is likely to be explored in future
clinical trials that promise to enhance our understanding of
this treatment paradigm.

Preclinical data supporting the use of RT with
immunotherapy

Radiation plus immunotherapy for metastatic
NSCLC

Beyond the benefits of direct cytotoxicity, radiotherapy
is associated with immunomodulatory effects that can
be leveraged in combination with immunotherapy (66).
Consequently, this also presents a greater opportunity for
targeting specific tumor-associated antigens (23,64,67).
Specific examples of radiotherapy-inducing tumorassociated antigens were demonstrated in carcinoembryonic
antigen (CEA)- and mesothelin-expressing tumors.
Radiotherapy has been shown to upregulate the expression
of the Fas gene in CEA-expressing tumor cells. Using
a mouse model, Chakraborty et al. highlighted that
radiotherapy enhanced Fas gene expression leading to
improved antitumor activity in the setting of CEA-based
vaccine therapy where T-cell killing proceeds through the
Fas/FasL pathway (68). Mesothelin is a cell surface protein
overexpressed in mesotheliomas, pancreatic, and ovarian
tumors (69). Hassan et al. demonstrated the dose-dependent
response of irradiated A4310K5 carcinoma cells resulting in
elevated extracellular mesothelin expression and enhanced
antitumor activity of an anti-mesothelin immunotoxin
against mesothelin-expressing tumor xenografts. Additional
examples of increased tumor associated antigens following
radiotherapy include c-met and HER2 (70,71). Beyond
enhancing tumor-associated antigens, radiotherapy also has
been shown to address some of the barriers to effective T-cell
therapy related to trafficking and chemotaxis (72-74).
Preclinical studies demonstrating the treatment
synergy between CAR T-cell therapy and radiotherapy
are encouraging (75,76). Radiotherapy appears to be a

More than half of patients with NSCLC present with distant
metastases at the time of diagnosis (77). Unfortunately,
long-term survival for patients with stage IV NSCLC is
rare with 5-year overall survival (OS) less than 5% (77). For
patients with stage IV NSCLC, RT has historically been
used only for palliative purposes and has not been thought
to improve survival over chemotherapy alone. However,
two recent randomized clinical trials have demonstrated
that in appropriately selected NSCLC patients with a low
burden of metastatic disease to a limited number of distant
sites (oligometastatic), RT can improve progression-free
survival (PFS) and potentially OS (78,79). This revelation,
along with the preclinical findings of the potential synergy
of RT with immunotherapies has opened up an exciting
new indication for RT in patients with metastatic NSCLC.
Platinum-based doublet chemotherapy has historically
been the standard first-line systemic therapy regimen
for patients with metastatic NSCLC without activating
mutations in epidermal growth factor receptor (EGFR)
or translocations in anaplastic lymphoma kinase (ALK)
or ROS1 (80). Taxane-based regimens have historically
been utilized as second-line regimens for patients that
have progressive disease after receiving a platinum-based
regimen (81). In 2015, results of the CheckMate 017
trial revolutionized systemic therapy for NSCLC. That
trial randomized patients with metastatic NSCLC who
had progressed during or after first-line chemotherapy
to docetaxel or the PD-1 inhibitor, nivolumab, found
a significant improvement in median OS along with
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significantly fewer serious treatment-related adverse events
(AEs) in the nivolumab arm (52). Similarly, the nearly
identical KEYNOTE-010 and POPLAR trials found
significant improvements in OS and fewer serious AEs in
patients receiving the PD-1 inhibitor pembrolizumab, or
the PD-L1 inhibitor atezolizumab, respectively, in patients
with metastatic NSCLC that had progressed during or
after first-line chemotherapy (82,83). PD-L1 expression
≥1% on tumor cells was required in the KEYNOTE-010
trial. Based on the results of these ground-breaking clinical
trials, the FDA approved nivolumab, pembrolizumab,
and atezolizumab for second-line treatment of metastatic
NSCLC.
Two recent clinical trials have demonstrated that ICIs
are also effective as first-line therapy for select patients with
metastatic NSCLC. The KEYNOTE-024 trial randomized
patients with treatment-naïve metastatic NSCLC without
sensitizing EGFR mutations or ALK rearrangements
and with PD-L1 expression ≥50% to pembrolizumab or
platinum-based chemotherapy. The investigators found
that response rate and OS were significantly better in the
pembrolizumab group compared to the chemotherapy
group and fewer severe AEs occurred in the pembrolizumab
group. Based on the results of this trial, the FDA approved
pembrolizumab for first-line treatment of patients with
metastatic NSCLC whose tumors express PD-L1 on
≥50% of tumor cells (84). The KEYNOTE-189 trial
randomized patients with treatment-naïve metastatic nonsquamous NSCLC without sensitizing EGFR mutations or
ALK rearrangements regardless of PD-L1 expression to a
platinum-based chemotherapy doublet with pembrolizumab
or the same chemotherapy regimen plus placebo. Patients
on the pembrolizumab arm had significantly higher OS and
PFS regardless of PD-L1 expression levels, with similar
rates of severe AEs (85).
The rapid adoption of ICIs for metastatic NSCLC
and the frequent need for palliative RT for this patient
population have resulted in a number of retrospective
analyses reporting the safety and efficacy of combining ICIs
with RT. Hubbeling et al. reported no significant difference
in RT-related AEs in patients with metastatic NSCLC
receiving cranial RT that previously or concurrently
received PD-1/PD-L1 inhibitors compared to patients
receiving cranial RT who were PD-1/PD-L1 inhibitor
naïve (86). This and other early clinical data indicating that
combining RT with ICIs may be safe, and the promising
preclinical data demonstrating potential increased efficacy
with the combination has led to at least 4 ongoing
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prospective clinical trials evaluating the safety and efficacy
of the combination of RT and PD-1/PD-L1 inhibitors for
metastatic NSCLC, and an additional 8 trials combining
RT with other immunotherapy agents or combinations of
ICIs (Table 1). Many studies are evaluating hypofractionated
regimens, usually via stereotactic body radiation therapy
(SBRT), rather than lower doses of RT typically used in
the palliative setting, in hopes of eliciting greater antigen
release in an attempt to improve the efficacy of the ICIs.
The results of these clinical trials, expected in the next
few years, will greatly enhance our understanding of the
potential for RT to synergize with ICIs to provide clinically
meaningful improvements in outcomes of patients with
metastatic NSCLC.
Radiation plus immunotherapy locally advanced
and early stage NSCLC
Locally advanced
Approximately one-quarter of patients with NSCLC
present with locally advanced disease with regional lymph
node involvement. For years, these patients have been
primarily treated with concurrent platinum-based doublet
chemotherapy and daily RT over 6 to 7 weeks. However,
long-term disease control rates with this approach are
limited. Two years after chemoradiation, nearly half of
patients develop distant metastases, and only 30% will
be alive without progressive disease (87). There were
not any major advances in this approach for many years
with randomized clinical trials of both induction (88) and
maintenance chemotherapy (89) failing to consistently
demonstrate improvements in OS. Dose escalation with
conventional radiation even seems to decrease OS for
patients with locally advanced disease (87).
While there have been other studies looking at vaccines
as immunotherapy for patients with locally advanced
NSCLC (10,90,91), START (Stimulating Targeted
Antigenic Response To non-small-cell lung cancer) was
the earliest randomized phase III clinical trial to add
immunotherapy consolidation after chemoradiation for
locally advanced NSCLC (9). It assessed the efficacy of
tecemotide, a mucin 1 (MUC1) antigen-specific liposome
vaccine injected subcutaneously. In earlier studies, it was
capable of inducing a T-cell response in both mouse
models and patients. A single-arm phase 2 trial after
chemoradiation showed promising results (92). START
enrolled 1,513 patients and randomized them in a 2:1 ratio
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II

II

II

I/II

NCT03176173

NCT03313804

NCT02839265

NCT03168464

Table 1 (continued)

I

NCT02463994

I

II

NCT02434081

NCT03509584

I

NCT02621398

n/a

II

NCT03383302

NCT03035890

II randomized

NCT03446911

II

II randomized

NCT03148327

NCT03237377

I/II

NCT03050554

I

I

NCT02599454

NCT03245177

II randomized

NCT03110978

National clinical
Phase
trial ID number
NSCLC

Histology

NSCLC

NSCLC

NSCLC

NSCLC

NSCLC

NSCLC

NSCLC

NSCLC

NSCLC

NSCLC

NSCLC

NSCLC

Weill Medical College of
Cornell University

NSCLC

Montefiore Medical Center NSCLC

University of Kentucky

Stanford University

Multicenter let by
University of Michigan

Assistance Publique
Hôpitaux De Marseille

West Virginia University

Johns Hopkins University

University of Manchester

European Thoracic
Oncology Platform

Multicenter led by Rutgers NSCLC
Cancer Institute of New
Jersey

Multi Center led by Royal
Marsden

VU Medical Center

UCLA

UC San Diego

UC Davis and David Grant NSCLC
United States Air Force
Medical Center

MD Anderson Cancer
Center

Participating institution(s)

IV

IV

IV

IV

IV

IV

IV

IIIA

III

IIIA–IIIB

II–IIIB

I–II

I

I

I

I

I

Stage

Nivolumab/ipilimumab

CDX-301

Nivolumab/pembrolizumab/
atezolizumab

Nivolumab/pembrolizumab/
atezolizumab

Atezolizumab

Nivolumab/ipilimumab

Nivolumab/pembrolizumab/
atezolizumab

Durvalumab/tremelimumab

Pembrolizumab

Nivolumab concurrently with

Pembrolizumab concurrently
with carboplatin and paclitaxel

Nivolumab

Pembrolizumab

Durvalumab

Avelumab

Atezolizumab

Nivolumab

Immunotherapy agent

Table 1 Ongoing clinical trials investigating combining radiation therapy and immunotherapy for thoracic cancers

PD-1/CTLA-4

FLT3 ligand

PD-1/PD-1/PD-L1

PD-1/PD-1/PD-L1

PD-L1

PD-1/CTLA-4

PD-1/PD-1/PD-L1

PD-L1/CTLA-4

PD-1

PD-1

PD-1

PD-1

PD-1

PD-L1

PD-L1

PD-L1

PD-1

Hypofractionated RT

SBRT

SBRT or conventional
palliative RT

Hypofractionated RT

Hypofractionated RT

Hypofractionated RT

Hypofractionated RT

Conventionally
fractionated RT

Conventionally
fractionated RT

Conventionally
fractionated RT

Conventionally
fractionated IMRT or
3D-CRT

SBRT

SBRT

SBRT

SBRT

SBRT

SBRT

Immunotherapy
Radiation
mechanism of action
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Esophageal
squamous cell
carcinoma

Malignant
pleural
mesothelioma

SCLC

SCLC

NSCLC

NSCLC

NSCLC

Ludwig Institute for
Cancer Research

Washington University in
St Louis
Esophageal
cancer

Esophageal
cancer

European Organisation for Esophageal
Research and Treatment
cancer
of Cancer

Samsung Medical Center

Memorial Sloan Kettering
Cancer Center

Emory University

MD Anderson Cancer
Center

New York University

MD Anderson Cancer
Center

UC Davis

NSCLC

NSCLC

Histology

PD-1/CTLA-4

PD-L1/CTLA-4

PD-1

CTLA-4

PD-1/CTLA-4

Avelumab

PD-L1

Durvalumab and Tremelimumab PD-L1 and CTLA-4

Pembrolizumab with
carboplatin and etoposide

Ipilimumab

Nivolumab/ipilimumab

II–IV

IV

PD-1

PD-1/CTLA-4

Durvalumab/tremelimumab with PD-L1/CTLA-4
capecitabine and paclitaxel

Pembrolizumab

Inoperable
Nivolumab/ipilimumab with
T1N1–3M0 or FOLFOX
T2–3N0–3M0

Conventionally
fractionated RT

Intracavitary
brachytherapy

Conventionally
fractionated RT

Conventionally
fractionated RT

SBRT

Hypofractionated RT
and SBRT

Hyperfractionated or
Hypofractionated RT

Hypofractionated RT

Hypofractionated RT
or SBRT

Hypofractionated RT

SBRT

SBRT

Immunotherapy
Radiation
mechanism of action

IL-2/nivolumab/pembrolizumab IL-2/PD-1/PD-1

Nivolumab/ipilimumab

Durvalumab/tremelimumab

Immunotherapy agent

Inoperable
Durvalumab/tremelimumab with PD-L1/CTLA-4
T2–3N0M0 or 5-Flurouracil and
T1–3N1–3M0 cisplatin

Recurrent

Recurrent

Limited and
extensive
stage

IV

IV

IV

IV

IV

Stage

SBRT, stereotactic body radiation therapy; IL-2, interleukin-2; PD-1, programmed cell death protein 1; PD-L1, programmed death1ligand 1; CTLA-4, cytotoxic
T-lymphocyte-associated protein 4; FOLFOX, 5-flurouracil, leucovorin, oxaliplatin; RT, radiation therapy; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

I/II

I/II

NCT03399552

NCT02735239

II randomized

NCT02701400

I

I

NCT02402920

NCT02642809

II

NCT02221739

II randomized

III randomized

NCT03391869

NCT03437200

Pilot

NCT03224871

II

I

NCT03223155

NCT03377400

University of Wisconsin

Ib

NCT03275597
University of Chicago

Participating institution(s)

National clinical
Phase
trial ID number

Table 1 (continued)
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to immunotherapy consolidation versus placebo. This
trial showed no significant difference in OS for all patients
in the modified intention-to-treat population. However,
in a subset analysis of patients who received concurrent
chemoradiation therapy, median OS was 30.8 months with
immunotherapy compared to 20.6 months with placebo
(P=0.016). In those who received sequential chemotherapy
and RT, however, there was no difference in OS (P=0.38).
Importantly, this drug showed no increase in serious grade
3 or 4 AEs (9).
In a similar study design to START, PACIFIC
randomized patients to receive consolidation with the antiPD-L1 antibody durvalumab (at a dose of 10 mg given
intravenously per kilogram of body weight) or placebo
every 2 weeks until disease progression or 12 months,
whichever occurred first (93). Durvalumab was given
1–42 days after the conclusion of chemotherapy and RT. In
a report from a planned interim analysis, the median PFS
from randomization was 16.8 months with immunotherapy
versus 5.6 months with placebo (HR 0.52, P<0.001). The
other primary end-point, OS, has yet to be reported.
Secondary end points of response rate, duration of response,
and the median time to death or distant metastases were
all better with durvalumab. Grade 3 or 4 AEs occurred in
29.9% of patients receiving durvalumab and 26.1% of those
receiving placebo. The most common grade 3 or 4 AE
was pneumonia at 4.4% with durvalumab and 3.8% with
placebo.
Adoption of consolidation with durvalumab has been
mixed globally to date with many national health systems
awaiting the OS results before considering it standard of
care. The above PFS results, however, led to FDA approval
of durvalumab in the United States, as well as incorporation
as a standard of care in the National Comprehensive Cancer
Network guidelines for patients with stage III disease,
performance status 0–1, and no disease progression after 2
or more cycles of definitive chemoradiation (94). European
Society for Medical Oncology guidelines have not yet
incorporated durvalumab into national guidelines. A health
technology appraisal on this use of durvalumab is expected
to be published in January 2019 by the National Institute
for Health and Care Excellence in the United Kingdom.
There are other actively recruiting singe-arm trials that
are exploring other immunotherapy agents (Table 1). MD
Anderson Cancer Center is recruiting to DETERRED,
a study exploring the safety of MDPL3280A, a PD-L1
inhibitor, as part of consolidation therapy (NCT02525757).
There are two studies ongoing that are moving PD-1

© Journal of Thoracic Disease. All rights reserved.

S2499

inhibitors earlier in the treatment sequence at the same time
as concurrent chemotherapy and RT. In a Rutgers Cancer
Institute of New Jersey led multi-center trial, the safety
of adding pembrolizumab to carboplatin and paclitaxel
for patients with stage II–IIIB NSCLC (NCT02621398)
is being tested. A similar phase II study by the European
Thoracic Oncology Platform is evaluating pneumonitis
rates with the addition of 4 doses of nivolumab given
concurrently with standard concurrent chemotherapy
(NCT02434081). Both radiation and immunotherapy can
cause a similar presentation of pneumonitis, and to date,
there are little prospective data on the potential synergistic
toxicity of the combination. This combination is, therefore,
being approached with caution.
Early stage
Patients with NSCLC without regional nodal spread can
either undergo a resection or be treated with RT. SBRT has
emerged over the past decade as an effective treatment with
improved disease control and patient quality of life when
compared to conventionally fractionated radiation (95).
While primary tumor control is high with SBRT, systemic
recurrence remains problematic, and the predominant
method of failure. However, SBRT has been shown
anecdotally to cause an abscopal effect in patients receiving
immunotherapy for a variety of solid tumors, where after
the administration of radiation to one location, there is a
response in tumor(s) at distant sites. There is hope that this
combination in early stage NSCLC can reduce the rate of
nodal and distant recurrences. Trials are exploring whether
the combination of SBRT with immunotherapy can be
performed safely, as patients with early stage NSCLC have
longer life expectancies and thus are at risk of developing
long-term toxicities.
In the United States, there are at least four clinical trials
assessing the efficacy and safety of ICIs after SBRT for
early-stage NSCLC (Table 1). A multicenter phase I study
of atezolizumab, an anti-PD-L1 monoclonal antibody, in
combination with SBRT in high-risk early-stage NSCLC
is recruiting (NCT02599454) in order to determine the
maximum tolerated dose (MTD) of atezolizumab with
SBRT. A similar phase I/II study is recruiting at the
University of California, San Diego using the PD-L1
monoclonal antibody, avelumab (NCT03050554), and
two separate phase II are randomizing patients with earlystage NSCLC to SBRT with or without durvalumab
(NCT03148327) or nivolumab (NCT03110978),
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respectively.
In Europe, two trials will explore the tolerability
of combining SBRT and PD-1 antibodies (Table 1).
Tolerability is largely defined by the rate of grade 3 or
greater pneumonitis. At VU University Medical Center in
the Netherlands, patients with early stage node-negative
NSCLC will be randomized to receive either SBRT alone
or SBRT with 2 cycles of pembrolizumab followed by
lobectomy (NCT03446911). If the rate of grade 3 or greater
pneumonitis is ≤10%, the combination will be regarded as
safe. In Great Britain, STILE (NCT03383302) is a single
arm, multi-center phase II open-label study of nivolumab
given within 24 hours of the final fraction of SBRT then
every 2 weeks. If the rate of grade 3 or greater pneumonitis
exceeds 20% in the first 6 months, the combination will be
deemed unacceptable.
As these small studies attest, combining immunotherapy
and RT for early-stage NSCLC is still in its infancy.
Challenges with early-stage patients include appropriate
selection of the patients that are most likely to benefit from
combined modality treatment as well as optimal sequencing
and duration of immunotherapy. The optimal radiation dose
and fractionation for SBRT alone remain to be determined
for peripheral and central tumors, much less when SBRT
is combined with immunotherapy. Pseudoprogression after
immunotherapy also will likely make assessing response
only more challenging based on current RECIST size-based
criteria. Nonetheless, there is promising potential synergy
between radiation and immunotherapy to reduce systemic
failures and improve cure rates in early stage patients (96).
Radiation plus immunotherapy for SCLC
Despite a plethora of clinical trials for patients with SCLC
over the last two decades, little progress has been made
and patient outcomes remain poor, with OS ranging
between 10 and 30 months depending on extent of disease.
Although very responsive to first-line chemotherapy, SCLC
frequently relapses, and response to second-line agents
is extremely poor (97). Immunotherapy has thus been an
exciting development for SCLC as it has the potential to
overcome the limitations of chemotherapy by targeting
SCLC in a novel way.
The advent of immunotherapy has spurred a search
for biomarkers that can predict which patients may best
respond to ICIs. PD-L1 expression, though helpful, has
modest sensitivity and specificity (84). Numerous preclinical
and clinical studies have demonstrated that tumors with
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a high mutagenic burden, and thus high expression of
neoantigens, have high response rates to ICIs, irrespective
of levels of PD-L1 tumor expression (11). SCLC has long
been known to have a high tumor mutation burden (98).
This has been found to be correlated with response to
checkpoint inhibitors due to re-awakening of pre-existing
strong anti-tumor CD8+ cytotoxic T-cell responses (98,99).
There is also some pre-clinical and clinical evidence for
an immunomodulatory effect of SCLC tumor cells on
host immune system (100-102). The higher propensity of
paraneoplastic syndromes in SCLC is also hypothesized to
be evidence to suggest that several cross-reacting antibodies
recruited by the host immune response target both tumor
as well as normal cells. Apart from the immuno-stimulatory
effects, there is evidence to suggest that SCLC tumor cells
also exhibit a regulatory effect through induction of CD4+
Treg cells and decreased expression of HLA-class 1 antigen
on host immunity. This balance between the effector and
regulatory effects may distinguish extensive stage SCLC
(ES-SCLC) from limited stage SCLC (LS-SCLC) (103).
Both single and combination immunotherapy regimens
have been investigated in SCLC. The first agent evaluated
in ES-SCLC was the CTLA-4 antibody ipilimumab.
A number of studies, including a randomized phase III
trial evaluating it in combination with chemotherapeutic
agents in the first line setting, showed objective responses
but failed to meet their primary survival endpoints (104).
The KEYNOTE 028 study evaluated pembrolizumab
in previously treated ES-SCLC patients. It showed an
impressive response rate (RR) of 29% in unselected and
33.3% in PD-L1 expression-positive patients. Responses
were rapid and durable with a median duration of response
of 19.4 months and OS of 9.7 months. It was tolerated well
with an acceptable toxicity profile (105). The CheckMate
032 trial, which compared the combination of nivolumab
and ipilimumab with single-agent nivolumab as secondline therapy for ES-SCLC patients, showed a RR of
25%, compared to 11% with nivolumab alone and a near
doubling of OS (7.9 vs. 4.1 months, respectively) at the
expense of increased toxicity (106).
Although encouraging, priming with chemotherapy
alone may generate only subpar neoantigen expression and
a subsequent inadequate response. In this context, radiation
may enhance tumor immunogenicity by modulating the
immune response both at the systemic level and at the
level of the tumor microenvironment. There are currently
three trials evaluating the combination of radiation with
ICIs (Table 1). Investigators at MD Anderson Cancer
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Center are performing a phase-I dose escalation study of
pembrolizumab in combination with carboplatin, etoposide,
and RT in LS-SCLC and ES-SCLC (NCT02402920).
In Europe, the ongoing phase II randomized multicenter
STIMULI study is comparing standard chemoradiation
and prophylactic cranial irradiation followed by either
observation alone or 4 cycles of ipilimumab and nivolumab
followed by maintenance nivolumab for patients with LSSCLC (NCT02046733). Finally, Emory University is
conducting a randomized phase II study (NCT02701400)
evaluating the combination of tremelimumab and
durvalumab with or without hypofractionated RT or SBRT
in patients with relapsed SCLC. These studies will address
the toxicity concerns of combining these agents with
radiation, especially in the context of the relatively large
target volumes seen in SCLC as well as providing valuable
data on the appropriate dose, combination, and timing of
the treatments.
Radiation plus immunotherapy for mesothelioma
MPM is a rare disease with poor OS and limited effective
treatment options. The development of metastatic disease
is common, and there have not been significant strides
in cytotoxic chemotherapies in recent years. Patients
with MPM often have a large burden of disease and
poor performance status, thus the discovery of effective
immunotherapies has long been of interest. IL-2, IFN-alfa
2a and IFN-alfa 2b have been evaluated with mixed results
(107-109). A recent trial of chemotherapy and adenovirus
containing IFN-alfa 2b in previously treated patients
has resulted in an encouraging 21.5 months OS (109).
Unfortunately, the CTLA-4 inhibitor tremelimumab failed
to show an OS benefit in a recent phase III trial (110,111).
Anti PD-1/PD-L1 drugs, however, have shown promising
results in a series of small studies. Phase-I/II studies
incorporating pembrolizumab, nivolumab, and avelumab
have shown 9.4–20% partial response rates with stabilization
of disease in 50% of patients (112-114). Combined PDL1 inhibition is also being explored in two ongoing clinical
trials (NCT03048474 and NCT02899299). A report
from the University of Toronto found that the growth of
tumors in a murine mesothelioma model was significantly
reduced by hypofractionated radiation and combining
radiation with a CTLA-4 inhibitor enhanced the effect in
the irradiated and unirradiated tumors (115). Combining
radiotherapy and immunotherapy for mesothelioma is a
promising treatment strategy (116), and clinical data for the
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combination of radiation and ICIs are forthcoming. A single
arm phase II study has recently been initiated by Memorial
Sloan Kettering Cancer Center and will evaluate response
rates with Avelumab and SBRT in MPM (NCT03399552)
(Table 1).
Radiation plus immunotherapy for esophageal
cancer
Tr i m o d a l i t y t h e r a p y c o n s i s t i n g o f c o n c u r r e n t
chemoradiation followed by surgical resection is the
standard of care for locally advanced esophageal cancer
patients who are surgical candidates. The 5-year OS with
this approach ranges from 39–47% (117,118). In patients
that are medically inoperable or have unresectable disease,
definitive chemoradiation is recommended; however,
survival rates are poor and persistence of locoregional
disease occurs in nearly half of patients (119,120). More
aggressive treatments such as radiation dose-escalation and
the addition of targeted systemic agents against receptors
commonly expressed in esophageal cancer such as EGFR
have so far failed to improve patient outcomes (120,121).
PD-L1 expression is present in 45% of esophageal
cancer tissues and is associated with more locally aggressive
disease and decreased survival (122). Irradiated tumors
have been associated with an increased expression of PDL1 leading to suppression of anti-tumoral activity of
T-cells (16). Consequently, monoclonal antibodies directed
against PD-L1 receptors may act synergistically with
RT in killing tumor cells. This is the subject of several
ongoing phase I–II trials evaluating safety and efficacy of
the combination of chemoradiation with ICIs in both the
metastatic/inoperable (NCT03377400, NCT03437200,
NCT02642809) and neoadjuvant settings (NCT02735239)
(Table 1).
Radiation plus immunotherapy for thymoma
Thymomas represent 20% of all primary mediastinal
tumors (123). Surgical resection is the primary treatment.
Postoperative radiation is recommended in the presence
of positive margins and for advanced stages (4). While
survival outcomes are generally good, intrathoracic failures
after definitive treatment for thymoma can occur in
approximately up to one-quarter of patients (124). Due to
its rarity, there is a dearth of understanding of the molecular
biology of these tumors, and immunotherapy approaches
are limited to small patient cohorts. There are some studies
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suggesting PD-L1 expression has higher prevalence in
more aggressive histologies (i.e., B1-3 thymomas and
thymic carcinomas) and in higher Masaoka stages (125,126).
Avelumab was evaluated in 7 patients with locally advanced
thymoma and a partial response was observed in 4 of
these patients (127). There are two ongoing phase II trials
evaluating the efficacy of ICIs in thymomas (NCT02721732
and NCT02607631); however, none currently are in
combination with radiation. The efficacy of immunotherapy
combined with radiation will likely be of greater interest
as our understanding of thymoma tumor biology and its
interaction with the immune system improves.
Conclusions
The combination of immunotherapy and RT has the
potential to revolutionize treatments for thoracic
malignancies. Preclinical data have demonstrated impressive
synergy between the two therapies that appears to extend
beyond the irradiated target. For patients with advanced
NSCLC, recent clinical trials incorporating ICIs have
exhibited dramatic improvements in outcomes compared
to conventional chemotherapies. We anxiously await results
from ongoing and future preclinical research and clinical
trials to better define the optimal approaches to combining
these two pillars of cancer care.
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